REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy
Benzinga Newsdesk 4 months ago
News
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interestOn track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting potential approval in 2H
- Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest
- On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting potential approval in 2H 2027